Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
Purpose The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer. A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer. Methods O...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2010-08, Vol.66 (3), p.507-516 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 516 |
|---|---|
| container_issue | 3 |
| container_start_page | 507 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 66 |
| creator | Park, Yeon Hee Lee, Soohyeon Cho, Eun Yoon Choi, Yoon La Lee, Jeong Eon Nam, Seok Jin Yang, Jung-Hyun Ahn, Jin Seok Im, Young-Hyuck |
| description | Purpose The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer. A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer. Methods Out of 886 patients treated for metastatic breast cancer (MBC) between January 1995 and December 2006, 269 patients with HER2-positive tumors were identified. Of these, 198 patients with relapsed breast cancer following surgery were included in this study. Rates and patterns of relapse and metastatic spread in HER2+/ER+ and HER2+/ER− patients were analyzed. This analysis was evaluated by the validation patients' cohort of our institute prospectively. Results Median relapse-free survival was longer in the HER2+/ER+ group than in the HER2+/ER− group (32.0 vs. 19.5 months, p = 0.0012). The peak of recurrence occurred at 12 months after surgery in the HER2+/ER− patients. The peak of relapse was later and the level was lower in the HER2+/ER+ patients (66 and 78 months following surgery) than in the HER2+/ER− patients (33 and 39 months following surgery, respectively). This result was reproduced by the validation cohort with great similarity. Young age [hazard ratio (HR) 1.59, p = 0.002], TNM stage 3 (HR 1.51, p = 0.005), and ER-negativity (HR 1.68, p < 0.0001) were identified as independent risk factors for relapse. Severe bone metastasis (HR 4.48, p = 0.028) and massive hepatic metastasis (HR 5.24, p = 0.043) were identified as independent risk factors for early relapse. Conclusions Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status. |
| doi_str_mv | 10.1007/s00280-009-1190-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744623156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2060373931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-afc1098052321b8442520fa8dd7505e104c50c7cba468c9c435e001d15d19d2c3</originalsourceid><addsrcrecordid>eNqFkVGL1DAQx4Mo3t7qB_BFg3D4VJ1JJm3zeBynJxwo6j2HbJouPbrNmqSi396ULh74oE-ByW_-mcmPsRcIbxGgeZcARAsVgK4QNVTNI7ZBkqKCluRjtgFJVKkG6Iydp3QPAIRSPmVnqLWqtcINy59tzj5OiYeeRz_aY_LcTh0_-GxTtnlwPB2jtx0fJn5z_UVU4YeP_meppTRMe74rlylzZyfnI7fOhdgt9Ry4TzmGvZ9KsPPHHCJfEuf0jD3p7Zj889O5ZXfvr79d3VS3nz58vLq8rRypOle2dwi6BSWkwF1LJJSA3rZd1yhQHoGcAte4naW6ddqRVB4AO1Qd6k44uWVv1txjDN_nMo05DMn5cbSTD3MyDVEtJKr6_6SUkhSBKuTrv8j7MMeprGEUoIRWkigQrpCLIaXoe3OMw8HGXwbBLOrMqs4UdWZRVx7Yspen4Hl38N1Dx8lVAS5OgE3Ojn0sPz6kP5wQmmSLunBi5Yq3IsLHhwn_9fqrtam3wdh9LMF3X8WyELaqQWrkb5-7uYY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>501308342</pqid></control><display><type>article</type><title>Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Park, Yeon Hee ; Lee, Soohyeon ; Cho, Eun Yoon ; Choi, Yoon La ; Lee, Jeong Eon ; Nam, Seok Jin ; Yang, Jung-Hyun ; Ahn, Jin Seok ; Im, Young-Hyuck</creator><creatorcontrib>Park, Yeon Hee ; Lee, Soohyeon ; Cho, Eun Yoon ; Choi, Yoon La ; Lee, Jeong Eon ; Nam, Seok Jin ; Yang, Jung-Hyun ; Ahn, Jin Seok ; Im, Young-Hyuck</creatorcontrib><description>Purpose The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer. A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer. Methods Out of 886 patients treated for metastatic breast cancer (MBC) between January 1995 and December 2006, 269 patients with HER2-positive tumors were identified. Of these, 198 patients with relapsed breast cancer following surgery were included in this study. Rates and patterns of relapse and metastatic spread in HER2+/ER+ and HER2+/ER− patients were analyzed. This analysis was evaluated by the validation patients' cohort of our institute prospectively. Results Median relapse-free survival was longer in the HER2+/ER+ group than in the HER2+/ER− group (32.0 vs. 19.5 months, p = 0.0012). The peak of recurrence occurred at 12 months after surgery in the HER2+/ER− patients. The peak of relapse was later and the level was lower in the HER2+/ER+ patients (66 and 78 months following surgery) than in the HER2+/ER− patients (33 and 39 months following surgery, respectively). This result was reproduced by the validation cohort with great similarity. Young age [hazard ratio (HR) 1.59, p = 0.002], TNM stage 3 (HR 1.51, p = 0.005), and ER-negativity (HR 1.68, p < 0.0001) were identified as independent risk factors for relapse. Severe bone metastasis (HR 4.48, p = 0.028) and massive hepatic metastasis (HR 5.24, p = 0.043) were identified as independent risk factors for early relapse. Conclusions Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-009-1190-7</identifier><identifier>PMID: 19956951</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Adult ; Age Factors ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Bone Neoplasms - secondary ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer Research ; Cross-Sectional Studies ; Disease-Free Survival ; ER status ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; HER2-overexpressing breast cancer ; Humans ; Liver Neoplasms - secondary ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; metastasis ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Oncology ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Prospective Studies ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - metabolism ; Relapse pattern ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Time Factors ; Tumors</subject><ispartof>Cancer chemotherapy and pharmacology, 2010-08, Vol.66 (3), p.507-516</ispartof><rights>Springer-Verlag 2009</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-afc1098052321b8442520fa8dd7505e104c50c7cba468c9c435e001d15d19d2c3</citedby><cites>FETCH-LOGICAL-c456t-afc1098052321b8442520fa8dd7505e104c50c7cba468c9c435e001d15d19d2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-009-1190-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-009-1190-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22943819$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19956951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Yeon Hee</creatorcontrib><creatorcontrib>Lee, Soohyeon</creatorcontrib><creatorcontrib>Cho, Eun Yoon</creatorcontrib><creatorcontrib>Choi, Yoon La</creatorcontrib><creatorcontrib>Lee, Jeong Eon</creatorcontrib><creatorcontrib>Nam, Seok Jin</creatorcontrib><creatorcontrib>Yang, Jung-Hyun</creatorcontrib><creatorcontrib>Ahn, Jin Seok</creatorcontrib><creatorcontrib>Im, Young-Hyuck</creatorcontrib><title>Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer. A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer. Methods Out of 886 patients treated for metastatic breast cancer (MBC) between January 1995 and December 2006, 269 patients with HER2-positive tumors were identified. Of these, 198 patients with relapsed breast cancer following surgery were included in this study. Rates and patterns of relapse and metastatic spread in HER2+/ER+ and HER2+/ER− patients were analyzed. This analysis was evaluated by the validation patients' cohort of our institute prospectively. Results Median relapse-free survival was longer in the HER2+/ER+ group than in the HER2+/ER− group (32.0 vs. 19.5 months, p = 0.0012). The peak of recurrence occurred at 12 months after surgery in the HER2+/ER− patients. The peak of relapse was later and the level was lower in the HER2+/ER+ patients (66 and 78 months following surgery) than in the HER2+/ER− patients (33 and 39 months following surgery, respectively). This result was reproduced by the validation cohort with great similarity. Young age [hazard ratio (HR) 1.59, p = 0.002], TNM stage 3 (HR 1.51, p = 0.005), and ER-negativity (HR 1.68, p < 0.0001) were identified as independent risk factors for relapse. Severe bone metastasis (HR 4.48, p = 0.028) and massive hepatic metastasis (HR 5.24, p = 0.043) were identified as independent risk factors for early relapse. Conclusions Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - secondary</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer Research</subject><subject>Cross-Sectional Studies</subject><subject>Disease-Free Survival</subject><subject>ER status</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>HER2-overexpressing breast cancer</subject><subject>Humans</subject><subject>Liver Neoplasms - secondary</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Prospective Studies</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Relapse pattern</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkVGL1DAQx4Mo3t7qB_BFg3D4VJ1JJm3zeBynJxwo6j2HbJouPbrNmqSi396ULh74oE-ByW_-mcmPsRcIbxGgeZcARAsVgK4QNVTNI7ZBkqKCluRjtgFJVKkG6Iydp3QPAIRSPmVnqLWqtcINy59tzj5OiYeeRz_aY_LcTh0_-GxTtnlwPB2jtx0fJn5z_UVU4YeP_meppTRMe74rlylzZyfnI7fOhdgt9Ry4TzmGvZ9KsPPHHCJfEuf0jD3p7Zj889O5ZXfvr79d3VS3nz58vLq8rRypOle2dwi6BSWkwF1LJJSA3rZd1yhQHoGcAte4naW6ddqRVB4AO1Qd6k44uWVv1txjDN_nMo05DMn5cbSTD3MyDVEtJKr6_6SUkhSBKuTrv8j7MMeprGEUoIRWkigQrpCLIaXoe3OMw8HGXwbBLOrMqs4UdWZRVx7Yspen4Hl38N1Dx8lVAS5OgE3Ojn0sPz6kP5wQmmSLunBi5Yq3IsLHhwn_9fqrtam3wdh9LMF3X8WyELaqQWrkb5-7uYY</recordid><startdate>20100801</startdate><enddate>20100801</enddate><creator>Park, Yeon Hee</creator><creator>Lee, Soohyeon</creator><creator>Cho, Eun Yoon</creator><creator>Choi, Yoon La</creator><creator>Lee, Jeong Eon</creator><creator>Nam, Seok Jin</creator><creator>Yang, Jung-Hyun</creator><creator>Ahn, Jin Seok</creator><creator>Im, Young-Hyuck</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>20100801</creationdate><title>Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status</title><author>Park, Yeon Hee ; Lee, Soohyeon ; Cho, Eun Yoon ; Choi, Yoon La ; Lee, Jeong Eon ; Nam, Seok Jin ; Yang, Jung-Hyun ; Ahn, Jin Seok ; Im, Young-Hyuck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-afc1098052321b8442520fa8dd7505e104c50c7cba468c9c435e001d15d19d2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - secondary</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer Research</topic><topic>Cross-Sectional Studies</topic><topic>Disease-Free Survival</topic><topic>ER status</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>HER2-overexpressing breast cancer</topic><topic>Humans</topic><topic>Liver Neoplasms - secondary</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Prospective Studies</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Relapse pattern</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Yeon Hee</creatorcontrib><creatorcontrib>Lee, Soohyeon</creatorcontrib><creatorcontrib>Cho, Eun Yoon</creatorcontrib><creatorcontrib>Choi, Yoon La</creatorcontrib><creatorcontrib>Lee, Jeong Eon</creatorcontrib><creatorcontrib>Nam, Seok Jin</creatorcontrib><creatorcontrib>Yang, Jung-Hyun</creatorcontrib><creatorcontrib>Ahn, Jin Seok</creatorcontrib><creatorcontrib>Im, Young-Hyuck</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Yeon Hee</au><au>Lee, Soohyeon</au><au>Cho, Eun Yoon</au><au>Choi, Yoon La</au><au>Lee, Jeong Eon</au><au>Nam, Seok Jin</au><au>Yang, Jung-Hyun</au><au>Ahn, Jin Seok</au><au>Im, Young-Hyuck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2010-08-01</date><risdate>2010</risdate><volume>66</volume><issue>3</issue><spage>507</spage><epage>516</epage><pages>507-516</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer. A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer. Methods Out of 886 patients treated for metastatic breast cancer (MBC) between January 1995 and December 2006, 269 patients with HER2-positive tumors were identified. Of these, 198 patients with relapsed breast cancer following surgery were included in this study. Rates and patterns of relapse and metastatic spread in HER2+/ER+ and HER2+/ER− patients were analyzed. This analysis was evaluated by the validation patients' cohort of our institute prospectively. Results Median relapse-free survival was longer in the HER2+/ER+ group than in the HER2+/ER− group (32.0 vs. 19.5 months, p = 0.0012). The peak of recurrence occurred at 12 months after surgery in the HER2+/ER− patients. The peak of relapse was later and the level was lower in the HER2+/ER+ patients (66 and 78 months following surgery) than in the HER2+/ER− patients (33 and 39 months following surgery, respectively). This result was reproduced by the validation cohort with great similarity. Young age [hazard ratio (HR) 1.59, p = 0.002], TNM stage 3 (HR 1.51, p = 0.005), and ER-negativity (HR 1.68, p < 0.0001) were identified as independent risk factors for relapse. Severe bone metastasis (HR 4.48, p = 0.028) and massive hepatic metastasis (HR 5.24, p = 0.043) were identified as independent risk factors for early relapse. Conclusions Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>19956951</pmid><doi>10.1007/s00280-009-1190-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2010-08, Vol.66 (3), p.507-516 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_744623156 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Age Factors Aged Antineoplastic agents Biological and medical sciences Bone Neoplasms - secondary Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Research Cross-Sectional Studies Disease-Free Survival ER status Female Follow-Up Studies Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics HER2-overexpressing breast cancer Humans Liver Neoplasms - secondary Mammary gland diseases Medical sciences Medicine Medicine & Public Health metastasis Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Oncology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Prospective Studies Receptor, ErbB-2 - genetics Receptors, Estrogen - metabolism Relapse pattern Retrospective Studies Risk Factors Severity of Illness Index Time Factors Tumors |
| title | Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A58%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patterns%20of%20relapse%20and%20metastatic%20spread%20in%20HER2-overexpressing%20breast%20cancer%20according%20to%20estrogen%20receptor%20status&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Park,%20Yeon%20Hee&rft.date=2010-08-01&rft.volume=66&rft.issue=3&rft.spage=507&rft.epage=516&rft.pages=507-516&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-009-1190-7&rft_dat=%3Cproquest_cross%3E2060373931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=501308342&rft_id=info:pmid/19956951&rfr_iscdi=true |